An integrated framework for prognosis prediction and drug response modeling in colorectal liver metastasis drug discovery.

ABSTRACT:

Background

Colorectal cancer (CRC) is the third most prevalent cancer globally, and liver metastasis (CRLM) is the primary cause of death. Hence, it is essential to discover novel prognostic biomarkers and therapeutic drugs for CRLM.

Methods

This study developed two liver metastasis-associated prognostic signatures based on differentially expressed genes (DEGs) in CRLM. Additionally, we employed an interpretable deep learning model utilizing drug sensitivity databases to identify potential therapeutic drugs for high-risk CRLM patients. Subsequently, in vitro and in vivo experiments were performed to verify the efficacy of these compounds.

Results

These two prognostic models exhibited superior performance compared to previously reported ones. Obatoclax, a BCL-2 inhibit

SUBMITTER: Zhou X 

PROVIDER: S-EPMC10981831 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature